<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01914679</url>
  </required_header>
  <id_info>
    <org_study_id>NPT-201-UM</org_study_id>
    <nct_id>NCT01914679</nct_id>
  </id_info>
  <brief_title>A Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - University of Michigan</brief_title>
  <acronym>PERRFECT-UM</acronym>
  <official_title>A Phase 2 Clinical Trial Evaluating Use of the NeuroPoint Medical Device as a Treatment for Fibromyalgia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cerephex Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the mechanisms of noninvasive cortical
      electrostimulation therapy known as &quot;Reduced Impedance Noninvasive Cortical
      Electrostimulation&quot; RINCE)in the management of fibromyalgia. Patients who meet the 1990
      American College of Rheumatology criteria for fibromyalgia will receive up to 24 RINCE
      treatments delivered by a medical device called &quot;NeuroPoint&quot;. Approximately 20 patients will
      receive a combination of active and inactive (sham) therapy treatments over a 16-week period
      followed by a 4 week post-treatment evaluation. Patients will also undergo three (3)
      functional brain imaging scans while participating in the study: the first prior to the
      commencement of treatment, another mid-treatment; and the third at the completion of the
      treatment period.

      The study's primary outcome measure will be the change from baseline in self-reported 24-hour
      average pain intensity. The study's hypothesis is that there will be a change in pain
      intensity as well brain functioning. We do not expect there to be a statistically significant
      improvement in pain intensity due to the small sample but do expect to see statistically
      significant changes in cortical function as measured by EEG and fMRI
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor terminated the study
  </why_stopped>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>All participants went through a 4 week sham period, followed by a 12 week intervention with the device.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants did not know when the stimulation was occurring or not.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Patient 24-hour Recall Average Pain Intensity</measure>
    <time_frame>Assessed at Baseline (Week 1), Post-Sham (Week 5), Mid-Treatment (Week 10), Mid-Treatment (Week 14), Post-Treatment (Week 18)</time_frame>
    <description>The units of measure represent self-reported average pain over the last 24 hours on a 0-100 pain rating scale where 0 is no pain and 100 is the worst pain imaginable.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change in Network Connectivity as Measured by EEG</measure>
    <time_frame>Baseline (week 1), week 6, week 18 and week 21</time_frame>
    <description>EEGs will be measured at the baseline, week 4, week 18 and week 21 visits.</description>
  </other_outcome>
  <other_outcome>
    <measure>Investigate Changes in Neurocognitive Functioning Using the MASQ and MCS Assessments.</measure>
    <time_frame>Baseline and up to 21 weeks</time_frame>
    <description>The MASQ and MCS questionnaires will be administered at Baseline (week 1), week 6, week 10, week 14, week 18 and week 21.</description>
  </other_outcome>
  <other_outcome>
    <measure>fMRI Measures of Network Connectivity</measure>
    <time_frame>Baseline (week 1), week 6, and week 18</time_frame>
    <description>Subjects will undergo a neuroimaging scan at Baseline (week 1), week 6, and week 18. The scan will measure network connectivity during stimuli.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Sham followed by device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 weeks of inactive (sham) RINCE therapy involving no RINCE therapy followed by 12 weeks of RINCE therapy involving 24 total treatments</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RINCE</intervention_name>
    <description>The intervention is repeat applications of RINCE therapy. The sham is created by not delivering the therapy stimulation signal.</description>
    <arm_group_label>Sham followed by device</arm_group_label>
    <other_name>RINCE therapy delivered by NeuroPoint Device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must provide written informed consent and privacy authorization prior to
             participation in the study. Patient must have the ability to read and/or follow
             written and oral instructions, abide by the study restrictions, and agree to return
             for the required assessments.

          -  Patient is female, 18-65 years of age (inclusive) at the time of consent.

          -  Patient must have a confirmed diagnosis of fibromyalgia meeting the ACR 1990
             diagnostic criteria for fibromyalgia.

          -  Patients must have a 24-hour recall pain intensity score at both the screening and
             baseline visits between 40 and 90 inclusive on a 100 mm VAS scale.

          -  Female patient of childbearing potential must be willing to use an acceptable method
             of birth control for the duration of their study participation.

          -  Patients must be willing to refrain from all excluded therapies for the duration of
             the study.

          -  In the opinion of the Investigator, the patient is willing and able to comply with all
             protocol-specified requirements.

          -  Participants undergoing fMRI and 1H-MRS must be predominantly right handed (i.e. the
             subject writes with their right hand).

        Exclusion Criteria:

        The patient will not be eligible for enrollment if there is any history of, or in the
        opinion of the investigator, any of the following criteria are met:

          -  Patient has a current significant psychological or psychiatric disorder (e.g., severe,
             unstable or poorly controlled depression, severe anxiety or obsessive-compulsive
             disorder; history of suicide attempt within preceding 5 years or suicidal ideation
             within preceding 6 months; or any history of bipolar disorder, schizophrenia,
             schizoaffective or other psychotic disorder).

          -  Patient has a total Hospital and Anxiety Depression score of 11-21 for either anxiety
             or depression, or, based on the investigator's judgment, the patient is at risk of
             suicidal ideation or behavior.

          -  Patient is currently using prohibited medications or treatments (see Prohibited
             Concomitant Therapy section of protocol) including stimulants, anesthetic patches,
             CPAP and/or TENS therapy.

          -  Patient has an active diagnosis and is being treated for chronic infection or chronic
             condition such as lupus, rheumatoid arthritis, Parkinson's disease, multiple
             sclerosis, hepatitis, polio, seizures, or cancer (other than basal or squamous cell
             skin cancer).

          -  Patient has any other chronic pain condition other than fibromyalgia that, in the
             Investigator's opinion, would interfere with the assessment of fibromyalgia (e.g.,
             rheumatoid arthritis, post herpetic neuralgia, pain associated with diabetic
             neuropathy, severe pain due to degenerative joint disease, etc.)

          -  Patient has history of seizure disorder, dementia or epilepsy anytime during his or
             her life except pediatric febrile seizures.

          -  Female patient who is pregnant, planning a pregnancy, or breastfeeding.

          -  Patient has any other disease or medical condition that, in the opinion of the
             investigator, would interfere with the evaluation of study device efficacy or safety,
             or would compromise the patient's ability to participate in or complete the study.

          -  Patient has a history of other cranial electrical stimulation device use, or
             electroconvulsive therapy.

          -  Patient has any metal implant, such as stents, aneurysm clips, shunts, pacemakers,
             defibrillators, neurostimulators or other contraindications with fMRI and 1H-MRS.
             Long-bone implants are not excluded.

          -  Any anticipated need for surgery that might confound results or interfere with
             patient's ability to comply with the protocol.

          -  Myocardial infarction during preceding 12 months, uncontrolled hypertension, active
             cardiac disease (American Heart Association Functional Class 2, 3 or 4 or Objective
             Class C or D), clinically significant cardiac rhythm or conduction abnormality, or
             anticipation of bypass or other cardiac surgery within the next 12 months.

          -  Current systemic infection (e.g., HIV, hepatitis).

          -  Patients receiving systemic corticosteroids (&gt; 5 mg prednisone or equivalent per day).

          -  Pending or current litigation or disability claim (including Workman's Compensation).
             Patients currently receiving disability benefits will require medical monitor approval
             on a case-by-case basis.

          -  Patient has history of alcohol and/or drug abuse.

          -  Patient has participated in any investigational study within 30 days prior to
             Screening visit or is currently participating in another clinical trial.

          -  Patient has received any prior experimental treatment or therapy that, in the opinion
             of the medical monitor, would compromise the patient's ability to participate in the
             study.

          -  Patient is a staff member or relative of a staff member at either the investigative
             site or the Cerephex Corporation.

          -  Body Mass Index (BMI) of greater than approximately 40 kg/m2.

          -  Claustrophobia or any other factor sufficiently significant that it is likely to
             prevent successful completion of fMRI and 1H-MRS procedures.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel J Clauw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2013</study_first_submitted>
  <study_first_submitted_qc>July 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2013</study_first_posted>
  <results_first_submitted>January 4, 2017</results_first_submitted>
  <results_first_submitted_qc>March 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2017</results_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Daniel Clauw, MD</investigator_full_name>
    <investigator_title>Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Fibromyalgia</keyword>
  <keyword>Pain</keyword>
  <keyword>Brain</keyword>
  <keyword>Stimulation</keyword>
  <keyword>Device</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sham and RINCE Treatment</title>
          <description>4 weeks of inactive (sham) RINCE therapy involving no RINCE therapy (8 treatments), and 12 weeks of RINCE therapy (24 treatments).
RINCE: The intervention is repeat applications of RINCE therapy. The sham is created by not delivering the therapy stimulation signal.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Began 12 Week Actual RINCE Treatment</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor terminated study</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sham and RINCE Treatment</title>
          <description>4 weeks of inactive (sham) RINCE therapy involving no RINCE therapy (8 treatments) and 12 weeks of RINCE therapy (24 treatments).
RINCE: The intervention is repeat applications of RINCE therapy. The sham is created by not delivering the therapy stimulation signal.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Patient 24-hour Recall Average Pain Intensity</title>
        <description>The units of measure represent self-reported average pain over the last 24 hours on a 0-100 pain rating scale where 0 is no pain and 100 is the worst pain imaginable.</description>
        <time_frame>Assessed at Baseline (Week 1), Post-Sham (Week 5), Mid-Treatment (Week 10), Mid-Treatment (Week 14), Post-Treatment (Week 18)</time_frame>
        <population>One participant missing from analysis at Week 14/Mid-Treatment/Visit 27 due to missed visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Sham and RINCE Treatment</title>
            <description>4 weeks of inactive (sham) RINCE therapy involving no RINCE therapy (8 treatments) and 12 weeks of RINCE therapy (24 treatments).
RINCE: The intervention is repeat applications of RINCE therapy. The sham is created by not delivering the therapy stimulation signal.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient 24-hour Recall Average Pain Intensity</title>
          <description>The units of measure represent self-reported average pain over the last 24 hours on a 0-100 pain rating scale where 0 is no pain and 100 is the worst pain imaginable.</description>
          <population>One participant missing from analysis at Week 14/Mid-Treatment/Visit 27 due to missed visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Week 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.42" spread="15.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Sham (Week 5)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.83" spread="29.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mid-Treatment (Week 10)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.50" spread="24.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mid-Treatment (Week 14)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.18" spread="23.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Treatment (Week 18)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.58" spread="24.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Network Connectivity as Measured by EEG</title>
        <description>EEGs will be measured at the baseline, week 4, week 18 and week 21 visits.</description>
        <time_frame>Baseline (week 1), week 6, week 18 and week 21</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Investigate Changes in Neurocognitive Functioning Using the MASQ and MCS Assessments.</title>
        <description>The MASQ and MCS questionnaires will be administered at Baseline (week 1), week 6, week 10, week 14, week 18 and week 21.</description>
        <time_frame>Baseline and up to 21 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>fMRI Measures of Network Connectivity</title>
        <description>Subjects will undergo a neuroimaging scan at Baseline (week 1), week 6, and week 18. The scan will measure network connectivity during stimuli.</description>
        <time_frame>Baseline (week 1), week 6, and week 18</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sham and RINCE Treatment</title>
          <description>4 weeks of inactive (sham) RINCE therapy involving no RINCE therapy (8 treatments) and 12 weeks of RINCE therapy (24 treatments).
RINCE: The intervention is repeat applications of RINCE therapy. The sham is created by not delivering the therapy stimulation signal.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Difficulty Focusing Vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach Flu (achiness, diarrhea, nausea, vomiting)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Food Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Stomach Pain/Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Stomach Cramps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Night Sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Shaking/Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cough/Congestion</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Yeast Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sinus Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Itchy Ears/Throat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Loss of Balance Resulting in Fall</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Ankle Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Leg cramp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental Fogginess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Bad Dreams</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Skin Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This mechanistic study wasnâ€™t powered to show statistically significant clinical improvement, even as originally planned. Sponsor terminated study early when they realized the devices were not delivering enough current to be of therapeutic benefit.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Daniel Clauw, MD</name_or_title>
      <organization>University of Michigan</organization>
      <phone>734-998-6901</phone>
      <email>dclauw@med.umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

